Organon & Co. is a pharmaceutical manufacturer focused on women's health, biosimilars, and established therapeutic products across multiple disease areas. The company develops and commercializes prescription therapies and medical devices globally, with operations spanning North America, Europe, Asia Pacific, Latin America, and other international markets.
The women's health segment comprises contraceptive products including Nexplanon and NuvaRing, fertility treatments such as Follistim AQ and Elonva, and medications for postpartum hemorrhage and bacterial vaginosis. The company's biosimilars portfolio includes immunology products like Brenzys and Renflexis, oncology biosimilars such as Ontruzant, and bone health agents. Additional revenue streams come from established brands in cardiovascular care (Cozaar, Hyzaar), cholesterol management (Zetia, Vytorin), respiratory and allergy treatments (Singulair, Nasonex), dermatology products, bone health (Fosamax), pain management, and specialty products for benign prostatic hyperplasia and male pattern hair loss.
Organon distributes its products through drug wholesalers, retailers, hospitals, clinics, government agencies, and pharmacy benefit managers. The company was established in 1923 and maintains its headquarters in Jersey City, New Jersey.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $0.72 | $0.72 | -78.4% | |
| 2024 | $3.33 | $3.36 | -16.5% | |
| 2023 | $3.99 | $4.01 | +11.1% | |
| 2022 | $3.59 | $3.61 | -32.4% | |
| 2021 | $5.31 | $5.33 | — |